Harmonic Pharma is a leading provider in the field of computational toxicology and machine learning-based methods for small molecules. With their exclusive services and software, they offer innovative solutions for sustainability and performance in drug development. Their flagship offering, SAFETY BY DESIGN®, focuses on using computational tools to enhance development decision-making and increase the probability of successfully bringing compounds to market, while ensuring compliance with regulatory requirements.

By leveraging Harmonic Pharma's predictive tools, such as Compound Toxicity Profiles (CTP) and the Rediscovery Platform®, customers can gain important insights during the R&D stage and concentrate their efforts on the most promising compounds. This approach significantly reduces the number of compounds that need to be tested in bioassays, saving both time and money. Founded in 2009, Harmonic Pharma specializes in drug repurposing and has since developed a platform for investigating the mechanism of action of various chemicals.

They have also expanded their capabilities through AI-based solutions, providing comprehensive toxicity profiling. In 2017, Harmonic Pharma received support from Seqens group, strengthening their technological and polypharmacological portfolios. The executive team at Harmonic Pharma consists of industry veterans with extensive experience in R&D, pharmaceuticals, and technology innovation.

Their scientific board includes renowned experts in molecular modeling, data mining, and knowledge integration. As a trusted partner, Harmonic Pharma supports clients in making informed decisions throughout the product development process. Whether dealing with de novo development or life cycle management, Harmonic Pharma's services are tailored to address the needs of industries working with chemicals.

For more information, collaborations, or inquiries, visit their website or connect with Harmonic Pharma on social media. Copyright © 2023 Harmonic Pharma